Skip to content
Mushroom Retreats
RecruitingPhase 1NCT06796361

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Psilocybin is currently under investigation as potential treatment for various neuropsychiatric disorders. (The sponsor's summary, shortened.)

Eligibility and contacts on ClinicalTrials.gov

The registry record

Status
Recruiting
Phase
Phase 1
Conditions
Healthy
Intervention
Ketanserin 40mg plus Psilocybin 40mg; 40mg Psilocybin; 20mg Psilocybin; 10mg Psilocybin; 5mg Psilocybin; Placebo
Sponsor
University Hospital, Basel, Switzerland
Ages
25 Years to 75 Years
Sex
All
Healthy volunteers
Accepted
Enrolment
16 people (planned)
Start
21 April 2025
Primary completion
August 2026
Registry last updated
28 May 2025

Sites (1)

  • Clinical Trial Unit, Basel, Canton of Basel-City, Switzerland (recruiting)

How joining a trial works

Free to take part
Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
Screened first
Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
Eligibility is strict
Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
You may get a placebo
Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
Contact the study team through the registry
Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
Not medical advice
This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications

Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.

Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials